PTC Therapeutics, Inc. (PTCT)

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Translarna Revenue	208.12M	235.30M	321.07M
Translarna Revenue Growth	-11.55%	-26.71%	-3.51%
Emflaza Revenue	120.05M	146.36M	207.22M
Emflaza Revenue Growth	-17.98%	-29.37%	-18.77%
Sephience Revenue	-	111.15M	-
Upstaza/Kebilidi Revenue	57.56M	56.63M	16.91M
Upstaza/Kebilidi Revenue Growth	1.65%	234.81%	-10.23%
All Other Products Revenue	37.42M	37.26M	36.95M
All Other Products Revenue Growth	0.40%	0.86%	17.30%
Net Product Revenue	658.85M	586.70M	582.15M
Net Product Revenue Growth	12.30%	0.78%	-8.78%
Collaboration and License Revenue	12.27M	998.36M	304.00K
Collaboration and License Revenue Growth	-98.77%	328306.91%	-99.70%
Royalty Revenue	254.62M	244.22M	203.86M
Royalty Revenue Growth	4.26%	19.80%	20.73%
Translarna France Revenue	-	-98.63M	18.81M
Translarna France Revenue Growth	-	-	-18.49%
Manufacturing Revenue	-	-	1.66M
Manufacturing Revenue Growth	-	-	-78.39%
Revenue (Other)	-521.78M	-586.70M	-582.15M
Revenue (Total)	827.11M	1.73B	806.78M
Revenue (Total) Growth	-52.21%	114.51%	-13.97%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Collaboration and License Revenue	12.27M	998.36M	304.00K
Collaboration and License Revenue Growth	-98.77%	328306.91%	-99.70%
Royalty Revenue	254.62M	244.22M	203.86M
Royalty Revenue Growth	4.26%	19.80%	20.73%
Translarna France Revenue	-	-98.63M	18.81M
Translarna France Revenue Growth	-	-	-18.49%
Manufacturing Revenue	-	-	1.66M
Manufacturing Revenue Growth	-	-	-78.39%
United States - Net Product Revenue	340.91M	252.19M	207.22M
United States - Net Product Revenue Growth	35.18%	21.70%	-18.77%
Russia - Net Product Revenue	65.18M	100.45M	105.38M
Russia - Net Product Revenue Growth	-35.11%	-4.68%	22.57%
Brazil - Net Product Revenue	97.37M	65.66M	72.08M
Brazil - Net Product Revenue Growth	48.29%	-8.91%	22.99%
All Other Countries - Net Product Revenue	155.39M	168.41M	197.47M
All Other Countries - Net Product Revenue Growth	-7.73%	-14.72%	-17.21%
Revenue (Total)	827.11M	1.73B	806.78M
Revenue (Total) Growth	-52.21%	114.51%	-13.97%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue (US)	-	-	413.04M
United States Revenue (US) Growth	-	-	-22.31%
Non-US Revenue	-	-	393.74M
Non-US Revenue Growth	-	-	-3.06%
Revenue (Total)	827.11M	1.73B	806.78M
Revenue (Total) Growth	-52.21%	114.51%	-13.97%

Updated May 7, 2026. Data Source: Fiscal.ai.